[Tribbles pseudokinase 3 inhibits the adipogenic differentiation of human adipose-derived mesenchymal stem cells]

X S Bai1, L W Lv1, Y S Zhou1

  • 1Department of Prosthodontics, Peking University School and Hospital of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China.

Abstract

Insights

Tribbles pseudokinase 3 (TRIB3) inhibits the differentiation of human adipose-derived mesenchymal stem cells (hASCs) into fat cells. Reducing TRIB3 enhances adipogenesis, offering potential for tissue engineering.

Area of Science:

  • Stem Cell Biology
  • Molecular Biology
  • Tissue Engineering

Background:

  • Human adipose-derived mesenchymal stem cells (hASCs) are crucial for adipose tissue engineering and soft tissue regeneration.
  • Understanding the molecular regulation of hASC adipogenesis is vital for optimizing these applications.

Purpose of the Study:

  • To elucidate the role of Tribbles pseudokinase 3 (TRIB3) in the adipogenic differentiation of hASCs.
  • To identify TRIB3 as a potential therapeutic target for enhancing hASC-based regenerative strategies.

Main Methods:

  • Lentivirus-mediated knockdown (shTRIB3) and overexpression (TRIB3-over) of TRIB3 in hASCs.
  • Assessment of transfection efficiency using qRT-PCR and Western blot.
  • Evaluation of adipogenic differentiation via Oil Red staining and quantification of key adipogenic marker genes (PPARγ, CD36, C/EBPα, LPL).

Main Results:

  • Successful generation of TRIB3-knockdown and TRIB3-overexpressing hASCs confirmed by qRT-PCR and Western blot.
  • TRIB3 knockdown significantly promoted lipid droplet formation and upregulated adipogenic genes (PPARγ, CD36, C/EBPα).
  • TRIB3 overexpression suppressed lipid droplet formation and downregulated adipogenic genes (PPARγ, CD36, LPL).

Conclusions:

  • TRIB3 acts as an inhibitor of hASC adipogenic differentiation.
  • Modulating TRIB3 levels offers a novel strategy to control hASC differentiation for therapeutic applications.
  • The inhibitory mechanism of TRIB3 likely involves the PPARγ signaling pathway.

Related Concept Videos